Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342869 | 1.00 | MAPT (0.43) | MAPTSMN1; SMN2MGLLTLR8NPC1 | |
| SCHEMBL2319620 | 1.00 | MAPT (0.43) | MAPTSMN1; SMN2MGLLTLR8NPC1 | |
| SCHEMBL2314604 | 0.87 | RARB (0.51) | MAPTSMN1; SMN2NPC1RAB9ARARB | |
| SCHEMBL2310945 | 0.87 | RARB (0.51) | MAPTSMN1; SMN2NPC1RAB9ARARB | |
| SCHEMBL6910192 | 0.83 | CA1 (0.46) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL8198894 | 0.81 | ESR1 (0.41) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL10614683 | 0.78 | RAB9A (0.36) | MAPTSMN1; SMN2TLR8NPC1RAB9A | |
| SCHEMBL19718104 | 0.78 | TSHR (0.42) | MAPTSMN1; SMN2RAB9AALDH1A1MEN1 | |
| SCHEMBL6686810 | 0.78 | TSHR (0.50) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL2317651 | 0.77 | MAPT (0.35) | MAPTSMN1; SMN2MGLLTLR8NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315510-B2 | Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2016-04-19 | — | — | US | claimed |
| EP-3459955-B1 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | BIOLITEC UNTERNEHMENSBERATUNGS II AG (AT) | 2022-11-02 | — | — | EP | disclosed |
| EP-3459955-A1 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | biolitec Unternehmensbeteiligungs II AG (AT) | 2019-03-27 | — | — | EP | disclosed |
| EP-2350058-B1 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2018-10-24 | — | — | EP | disclosed |
| US-9315510-B2 | Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2016-04-19 | — | — | US | disclosed |
| US-20110206613-A1 | METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2011-08-25 | — | — | US | disclosed |
| EP-2350058-A2 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | CeramOptec GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010033678-A2 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | CERAMOPTEC INDUSTRIES, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206613-A1 | METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | PTDSS2, PTDSS1, DLST | MAPT 4449/4885SMN1; SMN2 3804/4885MGLL 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.